{"_id": "64fe7e2d1544b4d920499d06", "and": [{"or": [{"$or": [{"diagnosis": "malignancy"}, {"diagnosis": "malignancy"}]}, {"$or": [{"stage": "metastatic"}, {"stage": "unresectable"}]}]}, {"standard of care therapy exists": false}, {"standard of care therapy is effective": false}, {"ACT infusion prior to study enrollment": true}, {"$or": [{"ACT type": "ACT with tumor infiltrating lymphocytes (TIL)"}, {"ACT type": "human leukocyte antigen (HLA)-class I T cell receptor (TCR)-engineered lymphocytes"}, {"ACT type": "HLA-class II TCR-engineered lymphocytes"}, {"ACT type": "chimeric antigen receptor (CAR)-engineered T cells"}]}, {"prior ACT therapy completed": true}, {"$or": [{"radiographic progression of residual disease": true}, {"active disease observed on biopsy": true}]}, {"$or": [{"$and": [{"cancer type": "solid tumor patients"}, {"measurable disease": true}, {"$or": [{"longest diameter": {"$gte": 20}}, {"longest diameter": {"$gte": 15}}]}]}, {"$and": [{"cancer type": "leukemia or non-Hodgkin's lymphoma patients"}, {"measurable disease": true}]}]}, {"disease suitable for assessment by pre- and post-biopsies": true}, {"prior anti-programmed cell death (PD)-1 therapy": false}, {"prior anti-PD-ligand (L)1 therapy": false}, {"other immunotherapies": false}, {"prior anti-PD-1 therapy": false}, {"prior anti-PD-L1 therapy": false}, {"ACT completed": true}, {"residual disease documented": false}, {"ACT related toxicities resolved to grade 1": false}, {"alopecia": false}, {"vitiligo": false}, {"endocrine abnormalities requiring replacement therapy (grade 2)": false}, {"prior other anti-cancer therapy for 28 days prior to atezolizumab administration": false}, {"prior ACT therapy for 28 days prior to atezolizumab administration": false}, {"age": {"$gte": 18}}, {"ECOG performance status": {"$lte": 2}}, {"life expectancy": {"$gt": 90}}, {"absolute neutrophil count": {"$gte": 1000}}, {"platelets": {"$gte": 75000}}, {"$or": [{"hemoglobin": {"$gte": 8}}, {"hemoglobin": {"$gte": 8}}]}, {"total bilirubin": {"$lte": 1.5}}, {"$or": [{"aspartate aminotransferase (AST)": {"$lte": 3}}, {"alanine aminotransferase (ALT)": {"$lte": 3}}]}, {"$or": [{"AST": {"$lte": 5}}, {"ALT": {"$lte": 5}}]}, {"creatinine clearance": {"$gte": 30}}, {"INR and aPTT": {"$lte": 1.5}}, {"therapeutic anticoagulation": false}, {"adequate contraception for women of child-bearing potential and men": true}, {"pregnant women": false}, {"ability to understand and willingness to sign a written informed consent document": true}, {"chemotherapy or radiotherapy within 4 weeks prior to study entry": false}, {"not recovered from adverse events due to agents administered more than 4 weeks earlier": false}, {"$or": [{"hormone-replacement therapy or oral contraceptives": true}, {"herbal therapy": {"$gt": 7}}, {"palliative radiotherapy for bone metastases": {"$gt": 14}}]}, {"prior treatment with anti-CTLA-4 antibody": true}, {"$and": [{"$gt": 42}, {"history of severe immune-related adverse effects from anti-CTLA-4 antibody": false}]}, {"treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1": false}, {"treatment with systemic immunostimulatory agents within 6 weeks prior to cycle 1, day 1": false}, {"treatment with systemic immunosuppressive medications within 2 weeks prior to cycle 1, day 1": false}, {"$or": [{"acute, low dose, systemic immunosuppressant medications": false}, {"inhaled corticosteroids and mineralocorticoids": false}, {"low-dose supplemental corticosteroids for adrenocortical insufficiency": false}]}, {"bisphosphonate therapy for symptomatic hypercalcemia": true}, {"$and": [{"known primary central nervous system (CNS) malignancy": true}, {"asymptomatic untreated CNS disease": false}, {"asymptomatic treated CNS metastases": false}]}, {"known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies": false}, {"history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins": false}, {"known clinically significant liver disease": false}, {"past or resolved hepatitis B infection": false}, {"hepatitis C virus (HCV) antibody negative or HCV RNA positive": false}, {"history or risk of autoimmune disease": false}, {"history of immune related events to anti-CTLA-4": false}, {"controlled type 1 diabetes mellitus on a stable insulin regimen": false}, {"eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only": false}, {"history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan": false}, {"active tuberculosis (TB)": false}, {"RANKL inhibitor therapy": false}, {"severe infections within 4 weeks prior to cycle 1, day 1": false}, {"signs or symptoms of infection within 2 weeks prior to cycle 1, day 1": false}, {"major surgical procedure within 28 days prior to cycle 1, day 1": false}, {"administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1": false}, {"uncontrolled intercurrent illness": false}, {"previously tested positive for human immunodeficiency virus (HIV)": true}, {"$and": [{"stable regimen of highly active anti-retroviral therapy (HAART)": true}, {"requirement for concurrent antibiotics or antifungal agents": false}, {"CD4 count above 250 cells/mcL": true}, {"undetectable HIV viral load": true}]}, {"pregnant women": false}]}